Other Data Conference Call Transcripts Financial Year 2017 Q1 FY2017 Conference Call Transcript Postal Ballot Results 13.3.2017 AGM Date, Book Closure for Dividend, AGM, Record Date, Cut off Date Outcome of Board meeting 31.8.2017 Notice of AGM Financial Year 2016 Q4 and Full Year FY2016 Conference Call Transcript Concall to discuss the Sale of Certain Products in SpecChem Division Financial Year 2015 Vivimed_Q1_FY2015Conference_Call_Transcript Vivimed_Q2_FY2015Conference_Call_Transcript Vivimed_Q3_FY2015Conference_Call_Transcript Financial Year 2014 Q4 and Full Year FY2014 Conference Call Transcript Q3 FY2014 Conference Call Transcript Q2 FY2014 Conference Call Transcript Q1 FY2014 Conference Call Transcript Actavis Acquisition Call Transcript Financial Year 2013 Q4 FY2013 Earnings Call Transcript Q4 and Full Year FY2013 Conference Call Invite Q3 FY2013 Earnings Call Transcript Q2 FY2013 Earnings Call Transcript Q1 FY2013 Earnings Call Transcript Corporate Policies Financial Year 2017 Related Party Transactions Policy Succession – Policy Corporate Governance Code of Conduct Code of Conduct for Directors and Management Terms and Conditions of Appointment of Independent Directors Criteria of Making Payments to Non-Executive Directors Key Managerial Person Familarisation Programme for Independent Directors Policy on Determination of Materiality Insider Trading Policy (UPSI) Whistle Blowers Policy Policy on Material Subsidiary Archival Policy Risk Policy CSR Policy Environment, Health and Safety Policy Dividend Distribution Policy REMUNERATION POLICY IEPF Unclaimed Dividend Transferred Unclaimed Dividend Transferred to IEPF 2007-08 Unclaimed Dividend Transferred to IEPF 2008-09 Unclaimed Dividend Transferred to IEPF 2009-10 Investor Presentation Financial Year 2016 Investor Presentation May 2015 Postal Ballot Notice Financial Year 2018 Postal Ballot Notice Financial Year 2017 Postal Ballot Notice Press Releases Financial Year 2018 ESOP Allotment Results and dividend- MAY 2017 Re Constitution of Audit Committee Financial Year 2017 Announces Sale of Certain Products of its Subsidiary (Jul-16) Outcome of the Board Meeting Financial Year 2016 CCI Approval (Dec-15) Sale of Certain Products in SpecChem Division (Sep-15) Satisfactory Outcome of USFDA Inspection (Sep-15) Financial Year 2014 Q1 FY2014 Earnings Press Release Acquires a US FDA approved formulation manufacturing facility Clarification Receives the PIC/S GMP approval for one of its pharmaceuticals manufacturing facilities in Hyderabad Share Price Clarification Clarification on allotment of Equity Shares Allotment of Equity Shares Financial Year 2013 08-Mar-2013: Care Ratings Research Coverage Financial Year 2013 Reliance – Feb 2013 Sumedha – Dec 2012 Fullerton – Nov 2012 MSFL – Aug 2012 Sumedha – Jun 2012 Reliance – Jun 2012 Reliance – Apr 2012 Research Reports Financial Year 2015 Anand Rathi April 2015 Scheme of Amalgamation Financial Year 2017 Vivimed Letter to BSE (Sept 2017) Vivimed Letter to NSE (Sept 2017) Financial Year 2016 Observation Letter Regarding Scheme of Amalgamation – BSE (Apr 2016) Observation Letter Regarding Scheme of Amalgamation – NSE (Apr 2016) Scheme of Amalgamation – BSE (Aug 2014) Scheme of Amalgamation – NSE (Aug 2014) Creative Health Memorandum and Article of Association Klar Sehen Memorandum and Article of Association Octtantis Memorandum and Article of Association Vivimed Memorandum and Article of Association Alathur Change of Name (Aug 2013) Alathur FY2012 Financial Results Alathur FY2014 Financial Results Creative Health FY2014 Annual Report Creative Health FY2013 Annual Report Creative Health FY2012 Annual Report Klar Shen FY2014 Annual Report Klar Sehen FY2014 Financial Results Klar Shen FY2013 Annual Report Klar Shen FY2012 Annual Report Octtantis FY2014 Financial Results Octtantis FY2013 Financial Results Octtantis FY2012 Financial Results